14.07
Sarepta Therapeutics Inc stock is traded at $14.07, with a volume of 76.62M.
It is down -35.94% in the last 24 hours and down -32.23% over the past month.
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.
See More
Previous Close:
$21.97
Open:
$16.975
24h Volume:
76.62M
Relative Volume:
11.49
Market Cap:
$1.38B
Revenue:
$2.23B
Net Income/Loss:
$-248.39M
P/E Ratio:
-5.2323
EPS:
-2.69
Net Cash Flow:
$-697.55M
1W Performance:
-22.54%
1M Performance:
-32.23%
6M Performance:
-88.07%
1Y Performance:
-90.21%
Sarepta Therapeutics Inc Stock (SRPT) Company Profile
Name
Sarepta Therapeutics Inc
Sector
Industry
Phone
617-274-4000
Address
215 FIRST STREET, CAMBRIDGE, MA
Compare SRPT with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
SRPT
Sarepta Therapeutics Inc
|
14.07 | 1.79B | 2.23B | -248.39M | -697.55M | -2.69 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
459.81 | 120.40B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
542.52 | 61.30B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
320.53 | 41.06B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
564.59 | 34.29B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
294.55 | 27.09B | 3.81B | -644.79M | -669.77M | -6.24 |
Sarepta Therapeutics Inc Stock (SRPT) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jul-18-25 | Downgrade | Needham | Buy → Hold |
Jun-20-25 | Downgrade | William Blair | Outperform → Mkt Perform |
Jun-18-25 | Downgrade | TD Cowen | Buy → Hold |
Jun-17-25 | Initiated | Wolfe Research | Peer Perform |
Jun-16-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
Jun-16-25 | Downgrade | BofA Securities | Buy → Neutral |
Jun-16-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
Jun-16-25 | Downgrade | H.C. Wainwright | Neutral → Sell |
Jun-16-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Jun-16-25 | Downgrade | Piper Sandler | Overweight → Neutral |
Jun-06-25 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
May-08-25 | Downgrade | Evercore ISI | Outperform → In-line |
Apr-11-25 | Initiated | Wells Fargo | Overweight |
Apr-02-25 | Upgrade | H.C. Wainwright | Sell → Neutral |
Mar-31-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
Feb-11-25 | Initiated | Deutsche Bank | Hold |
Nov-27-24 | Reiterated | Needham | Buy |
Nov-25-24 | Initiated | H.C. Wainwright | Sell |
Nov-07-24 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
Oct-21-24 | Initiated | Jefferies | Buy |
Oct-10-24 | Resumed | Raymond James | Outperform |
Jul-29-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
Jun-26-24 | Downgrade | Citigroup | Buy → Neutral |
May-31-24 | Initiated | Piper Sandler | Overweight |
May-28-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
May-14-24 | Upgrade | Oppenheimer | Perform → Outperform |
Jan-31-24 | Initiated | BMO Capital Markets | Outperform |
Dec-13-23 | Resumed | Citigroup | Buy |
Dec-12-23 | Initiated | Deutsche Bank | Buy |
Nov-21-23 | Initiated | Wedbush | Outperform |
Oct-31-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
Oct-31-23 | Downgrade | Oppenheimer | Outperform → Perform |
Jun-23-23 | Downgrade | Evercore ISI | Outperform → In-line |
Apr-26-23 | Initiated | SMBC Nikko | Outperform |
Apr-04-23 | Initiated | Citigroup | Buy |
Mar-01-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Dec-22-22 | Reiterated | BTIG Research | Buy |
Dec-16-22 | Upgrade | UBS | Neutral → Buy |
Apr-04-22 | Resumed | Cantor Fitzgerald | Overweight |
Jan-05-22 | Reiterated | Needham | Buy |
Dec-09-21 | Upgrade | Oppenheimer | Perform → Outperform |
Nov-05-21 | Upgrade | JP Morgan | Neutral → Overweight |
Sep-15-21 | Upgrade | Guggenheim | Neutral → Buy |
Aug-05-21 | Upgrade | JP Morgan | Underweight → Neutral |
Jun-15-21 | Initiated | BTIG Research | Buy |
Apr-26-21 | Resumed | Credit Suisse | Neutral |
Jan-12-21 | Downgrade | Citigroup | Buy → Neutral |
Jan-11-21 | Downgrade | UBS | Buy → Neutral |
Jan-08-21 | Downgrade | JP Morgan | Overweight → Underweight |
Jan-08-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Jan-08-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
Nov-11-20 | Initiated | Berenberg | Hold |
Oct-28-20 | Initiated | UBS | Buy |
Aug-25-20 | Initiated | Raymond James | Outperform |
Aug-20-20 | Downgrade | Credit Suisse | Outperform → Neutral |
Mar-31-20 | Initiated | Mizuho | Buy |
Nov-01-19 | Initiated | Guggenheim | Buy |
Aug-21-19 | Reiterated | Needham | Buy |
Jul-09-19 | Reiterated | Morgan Stanley | Overweight |
Jul-01-19 | Reiterated | RBC Capital Mkts | Outperform |
Apr-12-19 | Initiated | Evercore ISI | Outperform |
Mar-11-19 | Reiterated | Credit Suisse | Outperform |
Oct-12-18 | Initiated | Bernstein | Outperform |
Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
Sep-26-18 | Reiterated | RBC Capital Mkts | Outperform |
Sep-14-18 | Resumed | BofA/Merrill | Buy |
Sep-06-18 | Initiated | Credit Suisse | Outperform |
Aug-01-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Jun-21-18 | Reiterated | Robert W. Baird | Outperform |
Jun-20-18 | Reiterated | Needham | Buy |
Jun-19-18 | Reiterated | H.C. Wainwright | Buy |
View All
Sarepta Therapeutics Inc Stock (SRPT) Latest News
What drives Sarepta Therapeutics Inc. stock priceExceptional earning trajectories - PrintWeekIndia
Levi & Korsinsky Notifies Sarepta Therapeutics, Inc. (SRPT) Shareholders of Class Action Lawsuit and August 25, 2025 Deadline - ACCESS Newswire
What analysts say about Sarepta Therapeutics Inc. stockFree Stock Selection - Autocar Professional
Bragar Eagel & Squire, P.C. Reminds Investors That Class - GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Hims & Hers and Sarepta and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP - GlobeNewswire
SRPT SECURITIES NEWS: Did Sarepta Therapeutics, Inc. - GlobeNewswire
Q1 Earnings Estimate for SRPT Issued By Leerink Partnrs - Defense World
Sarepta Therapeutics Inc. Stock Analysis and ForecastConsistently superior profits - Jammu Links News
Sarepta Therapeutics’ (SRPT) Hold Rating Reiterated at Needham & Company LLC - Defense World
StockWatch: Sarepta Shares Nosedive after LGMD Gene Therapy Patient Dies - Genetic Engineering and Biotechnology News
This Gene Therapy Maker Refuses to Halt Shipments After Patient Deaths - Men's Journal
Sarepta Therapeutics Announces Layoff of 493 Employees, Including 80 in Ohio, Amid FDA Scrutiny and Stock Decline - Hoodline
Gene therapy maker Sarepta tells FDA it won’t halt shipments despite patient deaths - WTOP
Gene therapy maker Sarepta tells FDA it won't halt shipments despite patient deaths - Yahoo Finance
Gene Therapy Maker Sarepta Tells FDA It Won't Halt Shipments Despite Patient Deaths - U.S. News & World Report
Sarepta Therapeutics lays off 500 employees amid FDA investigation, including 80 in Columbus - nbc4i.com
Sarepta to continue Elevidys shipments despite FDA request to halt - Seeking Alpha
Securities Fraud Litigation and Shareholder Returns: A Strategic Evaluation of Sarepta Therapeutics' ELEVIDYS Case - AInvest
M&T Bank Corp Reduces Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - Defense World
Sarepta Therapeutics: A Sell Signal Amid Safety Crises and Existential Risks - AInvest
Sarepta Therapeutics (NASDAQ:SRPT) Shares Gap Down Following Analyst Downgrade - Defense World
Sarepta Therapeutics (NASDAQ:SRPT) Reaches New 52-Week Low Following Analyst Downgrade - Defense World
Sarepta says it won't comply with FDA request to stop shipping gene therapy Elevidys - Reuters
Sarepta Therapeutics laying off nearly 500 employees, including 80 in Franklin County - 10TV
Sarepta CEO: ‘We Have, I Believe, a Very Laudable History of Being Extraordinarily Transparent’ - MedCity News
SRPT BREAKING NEWS: Sarepta Therapeutics, Inc. - GlobeNewswire
Is Sarepta Therapeutics Inc. a good long term investmentOutstanding capital growth - Jammu Links News
Securities Fraud Class Action Filed Against Sarepta Therapeutics, Inc. (SRPT)Levi & Korsinsky Reminds Investors of August 25, 2025 - ACCESS Newswire
Sarepta receives FDA request to halt ELEVIDYS shipments for some patients - StreetInsider
Sarepta Says Another Patient Died After Receiving Gene Therapy - Bloomberg.com
FDA Shuts Down Sarepta's Distribution of Gene Therapy Elevidys Following Patient Deaths - NeurologyLive
Sarepta Therapeutics Provides Statement on ELEVIDYS - Sarepta Therapeutics
SRPTSarepta Therapeutics Inc Latest Stock News & Market Updates - Stock Titan
Gene-therapy company to eliminate 21 Durham employees as part of major restructuring - WRAL.com
HHS Says FDA Requests Sarepta Therapeutics Suspend Distribution Of Elevidys And Places Clinical Trials On Hold For Multiple Gene Therapy Products Following 3 Deaths - TradingView
FDA prepares to ask Sarepta Therapeutics to stop all shipments of Duchenne muscular dystrophy therapy - The Boston Globe
SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
Exclusive-US FDA to ask Sarepta to stop shipments of gene therapy Elevidys, source says - MarketScreener
Exclusive: US FDA to ask Sarepta to stop shipments of gene therapy Elevidys, source says - Reuters
Sarepta Therapeutics laying off 80 employees in Ohio - WTTE
Sarepta Therapeutics crisis is huge blow to Duchenne families, company - statnews.com
Major biotech stock tumbles 35 percent after major rare disease setback - TheStreet
Sarepta Crashes Almost 40% On A Damning Move From The FDA - Investor's Business Daily
Elevidys' future said to be on ice after Sarepta reports patient death from separate gene therapy - FirstWord Pharma
FDA to Ask Sarepta to Stop Shipping Muscular Dystrophy Drug Elevidys - The New York Times
SRPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
Investors Urged to Contact Levi & Korsinsky for Information Before August 25, 2025Sarepta Therapeutics, Inc. (SRPT) - TradingView
Sarepta Stock (SRPT) Crashes 37% as FDA Scrutiny Mounts Over Gene Therapy Deaths - TipRanks
SRPT BREAKING NEWS: Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Announces Third Death -- Contact BFA Law by the August 25 Class Action Deadline - GlobeNewswire
Baird downgrades Sarepta Therapeutics stock rating on Elevidys safety concerns - Investing.com
Sarepta Therapeutics Inc Stock (SRPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):